Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them ...

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...